Participated · Seed · May 2019

EnteroBiotix is a clinical-stage biopharmaceutical company focused on full-spectrum microbiome therapeutics. Its lead product, EBX-102-02, is a next-generation full-spectrum microbiome therapeutic manufactured with proprietary processing technologies intended to enable safe, stable, orally delivered microbial ecosystem restoration. The company positions EBX-102-02 as a potential first disease-modifying therapy for IBS-C and advanced the candidate into a Phase 2b program following positive Phase 2a TrIuMPH trial results in 122 patients. The RISE Phase 2b trial is randomized, double-blind, placebo-controlled and plans to enroll around 300 patients in the UK, with first dosing expected in Q2 2026 and topline data due in H2 2027. EnteroBiotix is building a broader pipeline in high-value gastrointestinal indications associated with significant unmet need. EBX-102-02 is not approved for clinical therapeutic use outside of clinical trials or regulated programmes.

Participated · Equity · Dec 2018

Lightpoint Medical develops intraoperative imaging products, notably a robotic laparoscopic probe designed to detect cancer in real time and the LightPath® Imaging System. The LightPath system has already achieved commercial sales throughout Europe. The laparoscopic probe is intended to bring real-time cancer detection to minimally invasive and robotic surgery to improve tissue-sparing and clinical outcomes. The company will use new funding to commercialise the laparoscopic probe and support commercial growth of the LightPath system. It has secured a £5 million financing and previously raised more than £3 million in grant funding from the Horizon 2020 SME Instrument and Innovate UK. Management says the funds will prepare the company for commercial scale-up and a commercial launch of the laparoscopic probe. Lightpoint Medical, based in Rickmansworth, United Kingdom and Cambridge, Massachusetts, develops the EnLight™ fiberscope system that uses molecular imaging to reveal microscopic cancer deposits. The technology is intended to enable surgeons to identify cancerous tissue during procedures. The company will use the awarded funds to support clinical trials of EnLight™ in lymph node cancer and a range of gynecologic cancers at Memorial Sloan Kettering Cancer Center (MSK). Lightpoint will collaborate on the research with MSK’s Drs. Jan Grimm and Nadeem Abu-Rustum. The company is led by Founder and CEO Dr. David Tuch and is backed by business angels and other private investors. Lightpoint Medical develops surgical imaging technologies, including its lead products LightPath™ and EnLight™, to help surgeons detect cancer in real time and reduce the need for repeat operations. The company has clinical trials underway in breast, prostate and stomach cancer. Led by CEO Dr David Tuch, Lightpoint is UK-based and completed a Series A raise of £2m ($3.1m). The company intends to use the funds to bring LightPath and EnLight to the US and European markets in 2015. Its technology is positioned for intraoperative cancer detection to improve surgical outcomes and reduce follow-up procedures. Lightpoint Medical is a Rickmansworth, UK–based developer of innovative imaging technologies for cancer surgery. Founded in 2012 by Dr David Tuch, the company is developing a novel molecular imaging technology based on Cerenkov luminescence imaging. The technology is intended to help surgeons detect cancer in real time during surgery, providing more accurate treatment while sparing healthy tissue. In June 2013 the company raised £175K (approximately $270K) in seed funding. The round involved a mix of institutional and angel investors led by Oxford Technology Management.